Literature DB >> 475933

Haemodynamic effects of dobutamine with special reference to myocardial blood flow. A comparison with dopamine and isoprenaline.

J Stephens, H Ead, R Spurrell.   

Abstract

The haemodynamic effects of dobutamine (2.5 to 10 micrograms/min per kg) were determined in 5 patients without cardiac failure who were undergoing cardiac catheterisation for suspected coronary disease. Myocardial blood flow was determined by the coronary sinus thermodilution technique. Data were compared with those from two groups of 5 patients who received dopamine (4-8 micrograms/min per kg) and isoprenaline (0.005-0.025 micrograms/min per kg). Each drug was given in a lower and a higher dose, and all increased mean cardiac index (dobutamine, 18% and 39%; dopamine, 11% and 23%; isoprenaline, 15% and 44%). These increases were associated with significant increases in mean myocardial oxygen consumption (dobutamine, 38% and 61%; dopamine, 25% and 62%; isoprenaline, 20% and 45%). Mean myocardial blood flow was increased by each drug but mean myocardial oxygen extraction was decreased by isoprenaline, was increased by dopamine, and was unchanged by dobutamine. Each inotropic agent has a similar effect on myocardial oxygen consumption, but isoprenaline has a direct coronary vasodilator action while dopamine has a coronary vasoconstrictor action. Dobutamine has no direct effect upon coronary vascular tone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 475933      PMCID: PMC482110          DOI: 10.1136/hrt.42.1.43

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  31 in total

1.  EFFECTS OF NOREPINEPHRINE ON THE CORONARY CIRCULATION IN MAN.

Authors:  P M YURCHAK; E L ROLETT; L S COHEN; R GORLIN
Journal:  Circulation       Date:  1964-08       Impact factor: 29.690

Review 2.  REGULATION OF CORONARY BLOOD FLOW.

Authors:  R M BERNE
Journal:  Physiol Rev       Date:  1964-01       Impact factor: 37.312

3.  Effect of heart rate and intracoronary isoproterenol, levarterenol, and epinephrine on coronary flow and resistance.

Authors:  F B LEWIS; J D COFFMAN; D E GREGG
Journal:  Circ Res       Date:  1961-01       Impact factor: 17.367

4.  Effect of epinephrine and norepinephrine on coronary circulation.

Authors:  R M BERNE
Journal:  Circ Res       Date:  1958-09       Impact factor: 17.367

5.  The relation of cardiac effort to myocardial oxygen consumption and coronary flow.

Authors:  L N KATZ; H FEINBERG
Journal:  Circ Res       Date:  1958-09       Impact factor: 17.367

6.  Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index.

Authors:  S J Sarnoff; E Braunwald; G H Welch; R B Case; W N Stainsby; R Macruz
Journal:  Am J Physiol       Date:  1958-01

7.  Current research and problems of the coronary circulation.

Authors:  D E GREGG; D C SABISTON
Journal:  Circulation       Date:  1956-06       Impact factor: 29.690

8.  The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure.

Authors:  C V Leier; J Webel; C A Bush
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

9.  The effects of isoproterenol and dopamine on regional myocardial blood flow after stenosis of circumflex coronary artery.

Authors:  J H McClenathan; R A Guyton; R H Breyer; G E Newman; L L Michaelis
Journal:  J Thorac Cardiovasc Surg       Date:  1977-03       Impact factor: 5.209

10.  Effects of selective and non-selective beta-adrenergic blockade on coronary dynamics in man assessed by rapid atrial pacing.

Authors:  J Stephens; R Hayward; H Ead; L Adams; J Hamer; R Spurrell
Journal:  Br Heart J       Date:  1978-08
View more
  10 in total

Review 1.  Inotropic agents in the treatment of cardiogenic shock.

Authors:  H S Mueller
Journal:  World J Surg       Date:  1985-02       Impact factor: 3.352

2.  Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers.

Authors:  Sven Asmussen; Michael Salter; Donald S Prough; George C Kramer; Christer Svensen; Melinda Sheffield-Moore; Michael P Kinsky
Journal:  Shock       Date:  2014-11       Impact factor: 3.454

3.  Interventricular redistribution of myocardial blood flow during metabolic vasodilation.

Authors:  B D Guth; R Schulz; E Thaulow
Journal:  Pflugers Arch       Date:  1991-01       Impact factor: 3.657

Review 4.  Cardiac autonomic nerve stimulation in the treatment of heart failure.

Authors:  Mariko Kobayashi; Alex Massiello; Jamshid H Karimov; David R Van Wagoner; Kiyotaka Fukamachi
Journal:  Ann Thorac Surg       Date:  2013-06-05       Impact factor: 4.330

5.  Effects of dopamine and dobutamine on the myocardial and systemic circulation during and following cardiopulmonary bypass in dogs.

Authors:  H B Ward; S Einzig; R W Bianco; T Wang; J E Foker
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

6.  Optimal oxygen delivery in critically ill patients.

Authors:  K Reinhart; L Hannemann; B Kuss
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

7.  Selectivity of dobutamine for adrenergic receptor subtypes: in vitro analysis by radioligand binding.

Authors:  R S Williams; T Bishop
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

8.  A comparison of dopamine, dobutamine and isoproterenol in the treatment of shock.

Authors:  L I Worthley; P Tyler; J L Moran
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

9.  Cardiac contractile reserve parameters are related to prognosis in septic shock.

Authors:  Antoine Kimmoun; Nicolas Ducrocq; Sébastien Mory; Remi Delfosse; Laura Muller; Pierre Perez; Renaud Fay; Bruno Levy
Journal:  Biomed Res Int       Date:  2013-07-17       Impact factor: 3.411

10.  Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.

Authors:  Aimee L Brame; Janet J Maguire; Peiran Yang; Alex Dyson; Rubben Torella; Joseph Cheriyan; Mervyn Singer; Robert C Glen; Ian B Wilkinson; Anthony P Davenport
Journal:  Hypertension       Date:  2015-02-23       Impact factor: 10.190

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.